Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million and a net loss of $131.01 million. Despite these challenges, key milestones in drug development and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results